SOLIGENIX, INC. Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SOLIGENIX, INC. stock issued during period, value, conversion of units for the quarter ending 2013-12-31 was -$6.22K.
- SOLIGENIX, INC. stock issued during period, value, conversion of units for the quarter ending 2013-09-30 was $0.00.
- SOLIGENIX, INC. stock issued during period, value, conversion of units for fiscal 2014 was $1.94M, a 68.80% decline from fiscal 2013.
- SOLIGENIX, INC. stock issued during period, value, conversion of units for fiscal 2013 was $6.21M.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2014-12-31 | $1.94M 10-K · filed 2016-03-24 | |
| 2013-12-31 | -$6.22K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25 | $6.21M 10-K · filed 2015-03-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |